Ozempic vs Wegovy: Same Drug, Different Labels, Different Rules

Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone that slows stomach emptying, increases fullness signaling, and improves insulin response. Novo Nordisk first brought it to market as Ozempic in 2017 for type 2 diabetes, where its glucose control earned the approval. The weight loss seen in those diabetes trials drove a second development program at a higher dose, and the 2.4mg dose became Wegovy, approved for chronic weight management in 2021 after the STEP trials.

Nothing about the molecule differs between pens. The differences are dose ceilings, 2mg for Ozempic versus 2.4mg for Wegovy, the label on file at the FDA, and the commercial infrastructure around each: separate savings programs, separate formulary listings, separate prior authorization criteria. Understanding that the products are commercially distinct but chemically identical is the key to every practical decision that follows, because the system routes you by diagnosis and label, not by chemistry.

Insurance formularies treat the two products as different drugs. With a type 2 diabetes diagnosis, Ozempic enjoys broad coverage: most commercial plans and Medicare Part D include it, typically landing copays at $25-$100 per month with the manufacturer savings card. Without a diabetes diagnosis, Ozempic coverage is not available to you, and plans verify the diagnosis during prior authorization.

Wegovy rides the weight management lane, where coverage reached 38% of large employer plans in 2025 per Kaiser Family Foundation data, up from 24% in 2023, but remains excluded by Medicare Part D and most state Medicaid programs. Where covered, prior authorization typically requires BMI of 30 or higher, or 27 with a weight-related condition, and the savings card can bring copays to $25. Where not covered, NovoCare Pharmacy sells both directly, and it prices them by dose rather than by product. As of September 2026 NovoCare listed the Ozempic pen at $349 per month for 0.25mg, 0.5mg and 1mg and $499 for 2mg, and the Wegovy pen at $349 for 0.25mg through 2.4mg and $399 for 7.2mg, with either pen at $199 per month for your first two fills at the 0.25mg and 0.5mg starting doses. That introductory rate is time-limited: Novo Nordisk states pricing will be updated after December 31, 2026. Oral versions sit lower again, with the Ozempic pill listed from $149 per month at 1.5mg and the Wegovy pill at $149 for 1.5mg and 4mg, rising to $299 at 9mg and 25mg. Compounded semaglutide programs from telehealth providers run $99 to $299 per month as the budget lane, and are not FDA-approved. The decision tree is short: diagnosis first, formulary second, channel third.

Ozempic is FDA-approved for type 2 diabetes in adults, so asking for it to lose weight is asking for it off-label. That is a legal and routine physician prerogative, and it was common during the shortage years, but the reasons behind it have thinned out. Insurance does not cover off-label Ozempic for weight, and price no longer settles the question either way: through NovoCare in September 2026 the two pens carry the same $349 per month across the starting and middle doses, and the same $199 rate for your first two fills. The gap opens only at the top of the ladder, where Ozempic 2mg is $499 while Wegovy holds $349 through its full 2.4mg maintenance dose. What the off-label route actually costs you is the label: a 2mg ceiling instead of 2.4mg, no weight management indication, none of the STEP 1 evidence behind the dose you would be taking, and $499 rather than $349 if you titrate to the top. The main historical reason for the workaround, Wegovy supply shortages, resolved in 2025.

Two situations keep the question alive. Prediabetes with obesity sits in a gray zone: it does not qualify for Ozempic diabetes coverage under most plans, so pursuing it is usually a dead end at prior authorization, and the honest route is Wegovy criteria or self-pay. And if you already take Ozempic for type 2 diabetes, you are using it inside its approved label; no product switch is needed, though a dose conversation with your prescriber sometimes is. If anyone offers you "cheap Ozempic" outside these channels without a prescription, you are looking at the gray market, where FDA warning letters, counterfeit pens, and unverifiable sourcing live.

Your diagnosis answers the question, not your preference. With type 2 diabetes: Ozempic is your product, coverage is likely, and any weight effect comes inside the treatment you are already on; ask your prescriber about dose optimization if weight is a co-goal. With obesity or overweight plus a weight-related condition, and no diabetes: Wegovy is your product, and the path is formulary check, prior authorization if covered, NovoCare if not (listed in September 2026 at $349 per month through the 2.4mg maintenance dose and $399 at 7.2mg, or $199 for your first two fills through December 31, 2026), or compounded semaglutide if the branded price does not fit, which runs $99 a month at Strut Health, $179 at TrimRx and $299 ongoing at MEDVi after its $179 first month; compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.

One more comparison belongs in the decision: semaglutide versus tirzepatide. The SURMOUNT-5 head-to-head found tirzepatide (Zepbound) outperformed semaglutide 20.2% to 13.7% at 72 weeks, so if you are choosing a weight loss medication from scratch with budget flexibility, read our semaglutide vs tirzepatide comparison before settling the Ozempic-Wegovy question, which is really a question about which semaglutide package fits your insurance. Semaglutide holds the cardiovascular outcomes edge with the SELECT trial data showing 20% cardiac event reduction, which matters specifically if you already have heart disease.